about
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphomaPandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia.Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.[Persistent polyclonal B-cell lymphocytosis: study of 35 cases].Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression.Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature.Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone.Premature aging and immune senescence in HIV-infected children.FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening.Multiplex real-time PCR for prompt diagnosis of an outbreak of human parainfluenza 3 virus in children with acute leukemia.Genetic changes including gene copy number alterations and their relation to prognosis in childhood acute myeloid leukemia.Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish CooType I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation.A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.Aplastic Crisis Secondary to Parvovirus B19 Infection as the First Manifestation of an Undiagnosed Hereditary Spherocytosis: Report of a Pediatric Series of Spanish Patients.Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions.Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma.Primary Cutaneous Small/Medium CD4+T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and OutcomeStudies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemiaZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic LeukemiaMultilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational statusFavorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapySyndromic albinism and haemophagocytosisValidation of the 'French Acute Lymphoblastic Leukaemia Study Group FRALLE prognostic index' for paediatric Philadelphia-chromosome acute lymphoblastic leukaemiaActivated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia
P50
Q28270332-BD262F6C-76C4-46D9-B68B-2A22A87623FAQ30387338-48884691-1B03-4451-95C4-C31B7D543817Q33346486-DD62F8B7-F4E3-42DB-A95B-5DAA5A099691Q33614921-672B9371-CE84-47D9-9C74-55A58E11D578Q33844080-8EE855C8-AB73-4D2D-AA53-F117C7E30D3CQ34095636-052BBE45-2B32-411F-B3E1-A48852A46981Q34569216-1FD3711A-3ACC-40F1-B16C-D028970089BEQ35638228-0591A42A-011C-4693-839D-D2BDDDD3FCC5Q36713487-43225CBF-ACAB-40DF-A871-F5F2A9CC8488Q36903898-C736AE0B-6F23-4EA5-97CF-7AF6AF4C68D5Q37580317-7D5DF2E8-B58B-4975-9D54-8ECA76FCF985Q38321235-C433D585-8209-463B-92DE-29362EEA8C70Q38910415-C16EAA76-6F09-4DBC-AC9F-C40FDBE2C6FBQ41099201-E676B688-286B-46A8-A61B-AA6DAE445C2AQ42256586-C5113B61-DC5D-4C44-95BB-74F692DBE27EQ44546687-1560C082-E514-45AC-B002-CF8CDA140B9DQ45059032-AC5F9CF0-828B-49D1-A5E0-787A15F43730Q45646052-4950A8B5-8A38-40AE-97B1-49555B092D5AQ46067392-2B2F88E2-D619-42AA-B06D-57F906CA6C1BQ47723709-3F7340A7-E968-4277-ACBA-A7E99FE3A04FQ48121762-0AAC74D6-5D8E-4C6B-B61C-310E0B752FC2Q50936910-E912556B-DC0D-4FEB-95E7-E843DD18869AQ54341675-FEF92F5C-9642-4269-B810-9E9748CC1D4FQ54395593-EACFEFB9-330C-48EF-9951-5FA7A919AB4DQ54725522-1A042E24-AB38-4D22-AF65-163C062F5F4FQ57279365-2DB3FAD0-3C53-4D9E-B290-7DA23D49FA8FQ57279454-B52CC996-63B6-4BDD-AD12-938DD9123A68Q57279463-ED8CAFA0-CC57-4018-BF05-370064D0F872Q57786919-446AE8A7-F29B-4439-B4F7-F08EE53C73DAQ57786990-009B91AC-8A7B-4261-9992-C562DE9590BEQ62078641-63F4E26B-16B9-4E07-80FE-A75DEF818479Q84572717-A6A55804-FD22-49B7-9BD9-3AF36062ADEBQ84955030-3F00DDFE-B928-4B93-A45F-C05EC09F0B60Q87213276-46276865-D5CB-4A27-B9E0-B8A15237B37F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mireia Camós
@ast
Mireia Camós
@en
Mireia Camós
@es
Mireia Camós
@nl
Mireia Camós
@sl
type
label
Mireia Camós
@ast
Mireia Camós
@en
Mireia Camós
@es
Mireia Camós
@nl
Mireia Camós
@sl
prefLabel
Mireia Camós
@ast
Mireia Camós
@en
Mireia Camós
@es
Mireia Camós
@nl
Mireia Camós
@sl
P106
P1153
6603149037
P31
P496
0000-0003-3658-7942